Research.Patient.info
Neuromyelitis Optica Spectrum Disorder research hub
2 indexed studies · 2 currently recruiting
- recruitingPHASE2
Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder
This study is looking at a new medicine called inebilizumab for children and teenagers aged 2-17 with a rare condition called Neuromyelitis Optica Spectrum Disorder (NMOSD). It will check how the medicine works, how safe it is, and what effects it has on the body.
United States · Argentina · Brazil - recruitingPHASE3
A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)
This study is looking at a new medicine called Satralizumab for children aged 2-11 with a rare condition called Neuromyelitis Optica Spectrum Disorder (NMOSD). It will primarily check how the medicine moves through the body, with a broad look at how well it works and if it's safe.
United States · Argentina · China